{
  "content": "Amiodarone taken concomitantly with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone During transfer to oral amiodarone, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral amiodarone In amiodarone-treated patients who require additional antiarrhythmic therapy, the initial dose of such agents should be approximately half of the usual recommended dose.\n\nThe use of rate control and rhythm control medications concurrently in a patient with Atrial Fibrillation (AF) should be approached with caution.",
  "source": "https://www.droracle.ai/articles/24138/can-rate-control-and-rhythm-control-drug-should-be-given-together-in-patient-with-af",
  "chunk_id": "9a3a20d7-eb47-4a2d-a7be-ba08df0cc081",
  "similarity_score": 0.2622565031051636,
  "query": "amiodarone pharmacokinetics drug interactions CYP450 beta-blockers metabolism clearance atrial fibrillation dosing",
  "rank": 45,
  "title": "Should rate control and rhythm control medications be administered concurrently in a patient with Atrial Fibrillation (AF)?",
  "authors": "Dr.Oracle Medical Advisory Board & Editors",
  "year": "2025",
  "journal": "Not available",
  "reference": "Dr.Oracle Medical Advisory Board & Editors. (2025). Should rate control and rhythm control medications be administered concurrently in a patient with Atrial Fibrillation (AF)? Not available.",
  "doi": "Not available",
  "chunk_index": 6,
  "total_chunks": 16,
  "retrieved_at": "2025-07-24T21:58:09.739283"
}